Astellas Pharma plans to decide on executive personnel changes at the Annual General Meeting of Shareholders scheduled for June 19, 2026. Kenji Yasukawa will be reappointed as Representative Chairman, and Naoki Okamura will be reappointed as Representative President and CEO.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4503-20260427-01.pdf","jir_short_summary":"Astellas Pharma plans to decide on executive personnel changes at the Annual General Meeting of Shareholders scheduled for June 19, 2026. Kenji Yasukawa will be reappointed as Representative Chairman, and Naoki Okamura will be reappointed as Representative President and CEO.","jir_summary":"### Overview of Executive Personnel Changes\nAstellas Pharma has preliminarily decided at the 21st Annual General Meeting of Shareholders and Board of Directors meeting scheduled for June 19, 2026, to reappoint Kenji Yasukawa as Representative Chairman, Naoki Okamura as Representative President and CEO, and Katsuyoshi Sugita as Representative Executive Vice President. Additionally, reappointments and new appointments of outside directors and audit and supervisory committee directors have been announced. The newly appointed audit and supervisory committee director, Shigeki Takahara, possesses extensive experience in accounting and finance.\n\n### Planned Resignees and Future Structure\nOutside directors Takashi Tanaka, Eriko Sakurai, and Mika Nakayama are scheduled to resign. The Board composition after approval at the Annual General Meeting is also disclosed, aiming to ensure stability and continuity of the management structure. Executive personnel changes are important measures that contribute to strengthening corporate governance and promoting management strategies.","jir_financial_highlights":"Executive Personnel Changes: Unknown (To be formally decided at the Annual General Meeting of Shareholders on June 19, 2026)","jir_category":"","jir_hashtags":"#AstellasPharma, #ExecutivePersonnelChanges, #JapaneseStocks","jir_key_figures":"Candidate for Representative Chairman: Kenji Yasukawa (Reappointment)\nCandidate for Representative President and CEO: Naoki Okamura (Reappointment)\nCandidate for New Audit and Supervisory Committee Director: Shigeki Takahara","jir_meta_title":"\u3010Astellas Pharma\u30112026 Executive Personnel Changes Preliminarily Decided\uff5cFormal Decision at June Shareholders Meeting","jir_meta_description":"Astellas Pharma plans to formally decide the appointments of Representative Chairman and President CEO at the Annual General Meeting of Shareholders on June 19, 2026. The management structure will be refreshed, including new audit directors.","jir_og_title":"\u3010Astellas Pharma\u30112026 Executive Personnel Changes Preliminarily Decided\uff5cFormal Decision at June Shareholders Meeting","jir_og_description":"Astellas Pharma has preliminarily decided on the reappointments of Representative Chairman and President CEO. The new Audit and Supervisory Committee director has also been announced, with formal approval expected at the June 2026 Shareholders Meeting.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-42896","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n